HPV Vaccine Developers Honored With 2017 Lasker-DeBakey Award

The Albert and Mary Lasker Foundation reports that “The 2017 Lasker-DeBakey Clinical Medical Research Award honors two scientists whose technological advances enabled the development of human papillomavirus (HPV) vaccines, which prevent cervical cancer and other tumors. Douglas R. Lowy and John T. Schiller (both from the National Cancer Institute) took a bold but calculated approach toward a major public-health problem whose…

Details

Expedited Pathways/Higher Instance of Safety Related Labeling Changes

Mostaghim et al (BMJ 2017;358:j3837) recently published a study in the British Medical Journal that concludes that “Expedited development and regulatory review pathways can accelerate the availability of new drugs, but drugs approved through these pathways are associated with increased safety related label changes after approval, particularly for the types of changes representing the highest risk…

Details

OTC Monograph User Fees, Pre-submission Meetings and Electronic Submissions Possible

Although not included in FDARA, there is a reasonable possibility the proposed Over-the-Counter Monograph User Fee Program (OMUFA) will still become law. Assuming passage, OTC User Fees and electronic submissions will be required and sponsors will have the opportunity to engage in pre-submission meetings with FDA before requesting changes to OTC monographs. The process for effecting such…

Details

Commissioner Gottlieb Vows Action: Says Drug Makers Gaming System to Slow Generic Competition

USA Today reported on August 15 that “Drugmakers ‘game the system and game the rules’ through a patient safety program that allows them to keep generic drug companies from getting enough doses of their branded drug, said Gottlieb. Generic drugmakers need up to 5,000 doses to do the studies needed to prove their products are truly equivalent, he…

Details

China Joins ICH in Pursuit of Global Harmonization of Drug Development Standards

Theresa M. Mullin, Ph.D. of FDA reports “I am pleased to have been in China recently, when the China Food and Drug Administration (CFDA) submitted its membership application to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (also known as the International Council for Harmonisation or ICH).” Click here for the…

Details

FDA Product-Specific Guidances Page Updated; Nearly 50 New Guidances Added

On August 15, 2017, FDA updated its page entitled Product-Specific Guidances for Generic Drug Development. In October 2016 we reported that “FDA Adds 67 New/Revised Product Specific Bioequivalence Guidances.” This latest addition is noteworthy because it includes finalized bioequivalence guidances, which the Agency has not done since September 2015. Click here to see the additions…

Details

FDA OTC Monograph Changes Coming: User Fees, Pre-submission Meetings and Electronic Submissions

FDA User Fees for Reliance on the FDA OTC Monographs? Although not included in FDARA, there is a reasonable possibility the proposed Over-the-Counter Monograph User Fee Program (OMUFA) will still become law. Assuming passage, Over-the-Counter (OTC) User Fees and electronic submissions will be required and sponsors will have the opportunity to engage in pre-submission meetings…

Details